HK Stock Market Move | ASCENTAGE-B (06855) rose by more than 3%, revealing for the first time a novel mechanism in which orelabatine exerts its anti-tumor effects through regulating lipid metabolism.

ASCENTAGE-B (06855) rose more than 3%, as of the time of publication, it increased by 3.04% to 64.35 Hong Kong dollars, with a turnover of 46.0484 million Hong Kong dollars. On the news front, according to a message from Ascend Biopharmaceuticals, on November 25th, the company announced that the research results of the phase I clinical trial (NCT03594422) for its original new drug Alectinib (trade name: Nalitinib) for the treatment of gastrointestinal stromal tumors (GIST) have been successfully published in the international authoritative journal, "Signal Transduction and Targeted Therapy" (Impact Factor 52.7). The study results indicate that Alectinib has shown good efficacy and safety in SDH-deficient GIST and has revealed a new mechanism of action of Alectinib in anti-tumor effects through lipid metabolism regulation. This phase I study evaluated the safety and anti-tumor activity of Alectinib in 66 patients with unresectable/metastatic GIST/other solid tumors, including 26 patients with SDH-deficient GIST who had failed treatment with tyrosine kinase inhibitors (TKIs). It is reported that this is the largest prospective clinical trial conducted to date for this rare subtype of GIST.